These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36043775)

  • 21. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
    Rha JH; Shrivastava VP; Wang Y; Lee KE; Ahmed N; Bluhmki E; Hermansson K; Wahlgren N;
    Int J Stroke; 2014 Oct; 9 Suppl A100():93-101. PubMed ID: 22988894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
    Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
    Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
    Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety outcomes of early initiation of antithrombotic agents within 24 h after intravenous alteplase at 0.6 mg/kg.
    Chiba T; Yoshimoto T; Wada S; Shiozawa M; Yoshimura S; Kimura S; Inoue M; Toyoda K; Ihara M; Koga M
    J Neurol Sci; 2023 Feb; 445():120546. PubMed ID: 36657370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of Discrepancy between Measured versus Stated Weight on Hemorrhagic Transformation and Clinical Outcomes after Intravenous Alteplase Thrombolysis.
    Shin DH; Kang MJ; Kim JW; Shin DJ; Park HM; Sung YH; Kim EY
    Cerebrovasc Dis; 2017; 44(5-6):241-247. PubMed ID: 28848080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and radiological factors associated with unfavorable outcome after intravenous thrombolysis in patients with mild ischemic stroke.
    Kim DH; Lee DS; Nah HW; Cha JK
    BMC Neurol; 2018 Mar; 18(1):30. PubMed ID: 29544461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes with Alteplase at 0.6 mg/kg in Clinical Practice: THAWS2 Study.
    Yoshimura S; Koga M; Okada T; Inoue M; Miwa K; Fukuda-Doi M; Kondo R; Inoue T; Ichijo M; Ohtaki M; Nagakane Y; Itabashi R; Sakai N; Kimura K; Kamiyama K; Shiokawa Y; Yagita Y; Iwama T; Yakushiji Y; Kusumi M; Yamaki T; Uemura J; Yasuura A; Noshiro S; Fukunaga D; Yazawa Y; Aoki J; Yoshikawa M; Ihara M; Toyoda K;
    Cerebrovasc Dis; 2024; 53(1):46-53. PubMed ID: 37263235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous alteplase at 0.6 mg/kg for acute stroke patients with basilar artery occlusion: the stroke acute management with urgent risk factor assessment and improvement (SAMURAI) Recombinant tissue plasminogen activator registry.
    Miyagi T; Koga M; Shiokawa Y; Nakagawara J; Hasegawa Y; Furui E; Kimura K; Kario K; Okuda S; Yamagami H; Okada Y; Nezu T; Maeda K; Endo K; Minematsu K; Toyoda K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1098-106. PubMed ID: 23063059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early neurological deterioration in acute ischemic stroke patients after intravenous thrombolysis with alteplase predicts poor 3-month functional prognosis - data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China).
    Che F; Wang A; Ju Y; Ding Y; Duan H; Geng X; Zhao X; Wang Y
    BMC Neurol; 2022 Jun; 22(1):212. PubMed ID: 35672740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iodinated Contrast Agents Reduce the Efficacy of Intravenous Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients: a Multicenter Cohort Study.
    Chen Z; Xu C; Zhong W; Gong X; Hu H; Zhang X; Chen Y; Li Q; Luo Z; Chen Z; Lou M
    Transl Stroke Res; 2021 Aug; 12(4):530-539. PubMed ID: 32895894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between magnetic resonance angiography-diffusion-weighted imaging mismatch and clinical outcome in endovascular treatment for acute ischemic stroke: subgroup analysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism--Japan Registry.
    Deguchi I; Dembo T; Yoshimura S; Sakai N; Okada Y; Kitagawa K; Kimura K; Hyogo T; Yamagami H; Egashira Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1471-6. PubMed ID: 24685994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants.
    Matute MC; Masjuan J; Egido JA; Fuentes B; Simal P; Díaz-Otero F; Reig G; Díez-Tejedor E; Gil-Nuñez A; Vivancos J; Alonso de Leciñana M
    Cerebrovasc Dis; 2012; 33(3):231-9. PubMed ID: 22261670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of intravenous thrombolytic treatment in wake-up stroke: Experiences from a single center.
    Wiśniewski A
    Brain Behav; 2021 Jun; 11(6):e02152. PubMed ID: 33939326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
    Nisar T; Hanumanthu R; Khandelwal P
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104360. PubMed ID: 31501036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke.
    Tsivgoulis G; Katsanos AH; Christogiannis C; Faouzi B; Mavridis D; Dixit AK; Palaiodimou L; Khurana D; Petruzzellis M; Psychogios K; Macleod MJ; Ahmed N
    Ann Neurol; 2022 Sep; 92(3):349-357. PubMed ID: 35713213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Even Faster Door-to-Alteplase Times and Associated Outcomes in Acute Ischemic Stroke.
    Jung S; Rosini JM; Nomura JT; Caplan RJ; Raser-Schramm J
    J Stroke Cerebrovasc Dis; 2019 Dec; 28(12):104329. PubMed ID: 31607439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes of post-thrombolytic intracerebral hemorrhage in ischemic stroke patients.
    Norby KE; Siddiq F; Adil MM; Chaudhry SA; Qureshi AI
    Neurocrit Care; 2013 Apr; 18(2):170-7. PubMed ID: 23212243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.